CLINICAL DATA

+20 years of clinical validation.
200 research collaborations. 100s of publications


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD

Read More

MammaPrint® Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2 breast cancer in NBRST

Publication: ASCO 2023, Abstract #521 Authors: Peter D. Beitsch 1 , James V. Pellicane 2 , Lajos Pusztai 3 , Paul L. Baron 4 , Erin F. Cobain 5 , Mary K. Murray 6 , Andrew Ashikari 7 , Pond R. Kelemen 7 , Angela Marie Mislowsky 8 , Julie Barone 9 , Kenneth H. Cowan 10 , Rakhshanda Layeequr Rahman 11 , William C. Dooley 12 , Andrea Menicucci 13 , Christine Carruth 13 , M. William Audeh 13 , Pat W. Whitworth 14 , NBRST Investigators Group

Read More

FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols

Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.

Read More

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer

Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.

Read More

LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer at very low risk of metastasis

Publication: ASCO 2023, Abstract TPS615 Authors: Elise Deluche, Stefan Michiels, Daniele Fric, Christophe Perrin, Caroline Bailleux, Thomas Bachelot, Pascal Ko Kivok Yun, Gaetan De Rauglaudre, Marie-Ange Mouret-Reynier, Romauld Le Scodan, Ines Vaz-Luis, Magali Lacroix-Triki, Clara Guyonneau, Fabrice Andre

Read More

Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests

Publication: ESMO BREAST CANCER CONGRESS 2022AuthorsEsther Schuler(1), Sahra Uygun(2), Lorenza Mittempergher(3), Darina Pronin(3), Sammy Mee(2), Simon Bao(2), Tyson Cavness(2), Anke Witteveen(3), and Annuska Glas(3)1. Zotz|Klimas, MVZ Düsseldorf-Centrum GbR, Germany 2. Agendia Inc., Irvine, CA 3. Agendia NV., Amsterdam, NetherlandsBackgroundThe MammaPrint® 70-gene signature (70GS) risk of recurrence and BluePrint® 80-gene signature Read More